INTRODUCTION Brain disorders may exhibit shared symptoms and substantial epidemiological
comorbidity, inciting debate about their etiologic overlap. However, detailed study of …

… observed to be sensitive to statins (P = 0.008; difference in summary z scores = 0.18, 95%
CI 0.07 to 0.29) and on tests not previously administered (P = 0.04; difference in summary z …

… Blood pressure reduction resulted in 11% relative risk reduction of dementia in patients
with no prior cerebrovascular disease but this effect was not statistically significant (p = 0.21) …

Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous
studies; however, a large portion of the genetic risk for this disease remains unexplained. …

We undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease (AD)
involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 (3,941 …

We sought to identify new susceptibility loci for Alzheimer's disease through a staged
association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease …

Background Clinical trials have shown the benefits of cholinesterase inhibitors for the
treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits …

Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous
disease with multiple contributors to its pathophysiology, including vascular dysfunction…

The identification of subjects at high risk for Alzheimer’s disease is important for prognosis
and early intervention. We investigated the polygenic architecture of Alzheimer’s disease and …

… defined by having at least 1 SNP with p<0.001. In that analysis, there was a significant excess
of categories regardless of the threshold (p<0.05, p<0.01, p<0.001) for defining a category …